World Health Organization Issues Alert Over Critical Shortage of Obesity Injections

Under 10% of patients who could benefit from GLP-1 drugs including Wegovy can access them, caution the World Health Organization as it publishes its initial guidance on the drugs.

With over a billion individuals worldwide currently obese, it is advocating for more widespread and fairer availability to these injectable treatments.

Per forecasts, more than two billion will be living with obesity by 2030 without intervention.

"The latest guidelines affirms that obesity is a lifelong illness that can be managed with thorough and lifelong support," remarked its chief Tedros Adhanom Ghebreyesus.

Significant expense, insufficient output, and distribution challenges are major hurdles to widespread availability to the treatments that can help people shift substantial body mass, says the body.

Skinny Jab Scarcity

Even in the present most favorable scenario, the manufacturing of these medications would only suffice for around 100 million people – less than 10% of those who need them, per the health organization.

The guideline calls on countries and companies to expand availability, through measures such as voluntary licensing.

A patent on the active ingredient – the primary component of the drug Wegovy – is scheduled to end in a number of countries in 2026.

How Weight-Loss Injections Operate

The injections replicate a natural hormone to delay gastric emptying, reduce hunger and increase feelings of fullness so people reduce food intake.

People typically begin shedding pounds in the initial weeks of commencing the weekly injections.

Research suggests people may regain a significant portion within a year of halting the treatment, when their typical appetite return.

To be carrying excess weight increases your risk for contracting health problems, including diabetes, cardiovascular issues, stroke, and specific cancers.

Obesity impacts individuals in every country and was linked to over three and a half million fatalities worldwide in 2024, per the health agency.